Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade B 64.5 -1.23% -0.80
RARE closed down 1.23 percent on Thursday, May 24, 2018, on 88 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical RARE trend table...

Date Alert Name Type % Chg
May 24 Wide Bands Range Expansion 0.00%
May 24 Overbought Stochastic Strength 0.00%
May 23 180 Bullish Setup Bullish Swing Setup -1.23%
May 23 Wide Bands Range Expansion -1.23%
May 23 Overbought Stochastic Strength -1.23%
May 22 Slingshot Bullish Bullish Swing Setup 0.50%
May 22 NR7 Range Contraction 0.50%
May 22 Wide Bands Range Expansion 0.50%
May 22 Overbought Stochastic Strength 0.50%
May 21 Wide Bands Range Expansion -0.45%

Older signals for RARE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Is RARE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 71.99
52 Week Low 41.67
Average Volume 451,308
200-Day Moving Average 51.8704
50-Day Moving Average 55.0644
20-Day Moving Average 59.731
10-Day Moving Average 64.399
Average True Range 2.4909
ADX 32.15
+DI 26.64
-DI 10.7
Chandelier Exit (Long, 3 ATRs ) 59.2573
Chandelier Exit (Short, 3 ATRs ) 57.3327
Upper Bollinger Band 70.15
Lower Bollinger Band 49.312
Percent B (%b) 0.73
BandWidth 34.886407
MACD Line 3.2128
MACD Signal Line 2.9234
MACD Histogram 0.2894
Fundamentals Value
Market Cap 2.75 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -9.57
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 68.13
Resistance 3 (R3) 68.47 67.60 67.53
Resistance 2 (R2) 67.60 66.68 67.43 67.32
Resistance 1 (R1) 66.05 66.10 65.62 65.71 67.12
Pivot Point 65.18 65.18 64.96 65.01 65.18
Support 1 (S1) 63.63 64.26 63.20 63.29 61.88
Support 2 (S2) 62.76 63.68 62.59 61.68
Support 3 (S3) 61.21 62.76 61.48
Support 4 (S4) 60.87